Baidu
map

食品药品监督管理总局曝光8起虚假宣传广告

2015-09-06 佚名 健康时报

国家食品药品监督管理总局9月3日通告,近期,食品药品监管部门监测到4个药品和4个保健食品擅自发布含有夸大宣传治愈率或有效率,利用患者的名义、形象做功效证明和承诺等问题的虚假广告,欺骗和误导消费者。具体通告情况如下:一、违法广告所涉企业及产品情况:(一)西安大唐制药集团有限公司生产的药品“醒脾开胃颗粒(广告中标示名称:大唐奥舒)”。该产品通过电视媒介发布违法广告,宣称“大唐奥舒用了效果就是不一样,一

\

国家食品药品监督管理总局9月3日通告,近期,食品药品监管部门监测到4个药品和4个保健食品擅自发布含有夸大宣传治愈率或有效率,利用患者的名义、形象做功效证明和承诺等问题的虚假广告,欺骗和误导消费者。具体通告情况如下:

一、违法广告所涉企业及产品情况:

(一)西安大唐制药集团有限公司生产的药品“醒脾开胃颗粒(广告中标示名称:大唐奥舒)”。该产品通过电视媒介发布违法广告,宣称“大唐奥舒用了效果就是不一样,一天两小袋,胃肠病患者重新过上正常人的生活”等。

(二)沈阳东新药业有限公司生产的药品“固本延龄丸”。该产品通过电视媒介发布违法广告,宣称“久服还可返老还童;服用3天,症状减轻;长期服用,白发转黑”等。

(三)山西省吕梁中药厂生产的药品“回春如意胶囊”。该产品通过电视媒介发布违法广告,宣称“使用三周,前列消炎、急慢性肾炎得到康复”等。

(四)广西南珠制药有限公司生产的药品“消朦片”。该产品通过广播媒介发布违法广告,宣称“角膜炎、结膜炎、老花等,受外伤看不见,用了都能好,都看不见也无所谓,也能好”等。

(五)山东圣海保健品有限公司的保健食品“益普利生牌玛咖西洋参胶囊(广告中标示名称:玛卡)”。该产品通过报纸和电视媒介发布违法广告,宣称“吃了一年多,记忆力增强了,尿频尿急的毛病没有了,免疫力提高了,血糖也平稳了”等。

(六)海南百舒堂生物科技开发有限公司的保健食品“唐缘牌氨糖酪蛋白磷酸肽钙胶囊(广告中标示名称:傦中金氨糖)”。该产品通过报纸和电视媒介发布违法广告,宣称“服用15天,膝关节的疼痛就开始减轻了;服用三个月,就可以下床了;服用半年,消除各种症状,治愈骨病不易复发”等。

(七)武汉宝龙堂生物科技有限责任公司的保健食品“福宇鑫牌太美胶囊(广告中标示名称:U巢)”。该产品通过电视媒介发布违法广告,宣称“服用两个月能减肥8斤,睡眠有保证,皮肤比以前水嫩了”等。

(八)上海中智科技应用发展公司的保健食品“拉摩力拉牌玛卡片”。该产品通过电视媒介发布违法广告,宣称“消除更年期障碍,改善前列腺供血,降低慢性病发病率”等。

二、上述药品和保健食品广告均未依法取得广告批准文号,食品药品监管部门已将其违法行为移送有关部门查处。各省(区、市)食品药品监管部门要认真履行属地监管责任,加大对违法广告的跟踪监测工作力度,一经发现,要及时采取责令其产品暂停销售等措施,联合有关部门,严肃查处;并向社会公开处理结果。涉嫌犯罪的,移送公安机关追究刑事责任。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1683905, encodeId=0e471683905d1, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Thu Oct 08 05:53:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672349, encodeId=f06016e234971, content=<a href='/topic/show?id=95c58850418' target=_blank style='color:#2F92EE;'>#虚假#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88504, encryptionId=95c58850418, topicName=虚假)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ab626907756, createdName=doctor-chen9591, createdTime=Mon Feb 15 18:53:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57314, encodeId=47595e31497, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57315, encodeId=9b845e3151b, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57316, encodeId=54b25e316f9, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57317, encodeId=e9305e31765, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2015-10-08 zxl738
  2. [GetPortalCommentsPageByObjectIdResponse(id=1683905, encodeId=0e471683905d1, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Thu Oct 08 05:53:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672349, encodeId=f06016e234971, content=<a href='/topic/show?id=95c58850418' target=_blank style='color:#2F92EE;'>#虚假#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88504, encryptionId=95c58850418, topicName=虚假)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ab626907756, createdName=doctor-chen9591, createdTime=Mon Feb 15 18:53:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57314, encodeId=47595e31497, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57315, encodeId=9b845e3151b, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57316, encodeId=54b25e316f9, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57317, encodeId=e9305e31765, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1683905, encodeId=0e471683905d1, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Thu Oct 08 05:53:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672349, encodeId=f06016e234971, content=<a href='/topic/show?id=95c58850418' target=_blank style='color:#2F92EE;'>#虚假#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88504, encryptionId=95c58850418, topicName=虚假)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ab626907756, createdName=doctor-chen9591, createdTime=Mon Feb 15 18:53:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57314, encodeId=47595e31497, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57315, encodeId=9b845e3151b, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57316, encodeId=54b25e316f9, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57317, encodeId=e9305e31765, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-14 medsic

    唉……

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1683905, encodeId=0e471683905d1, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Thu Oct 08 05:53:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672349, encodeId=f06016e234971, content=<a href='/topic/show?id=95c58850418' target=_blank style='color:#2F92EE;'>#虚假#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88504, encryptionId=95c58850418, topicName=虚假)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ab626907756, createdName=doctor-chen9591, createdTime=Mon Feb 15 18:53:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57314, encodeId=47595e31497, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57315, encodeId=9b845e3151b, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57316, encodeId=54b25e316f9, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57317, encodeId=e9305e31765, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-14 medsic

    唉……

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1683905, encodeId=0e471683905d1, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Thu Oct 08 05:53:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672349, encodeId=f06016e234971, content=<a href='/topic/show?id=95c58850418' target=_blank style='color:#2F92EE;'>#虚假#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88504, encryptionId=95c58850418, topicName=虚假)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ab626907756, createdName=doctor-chen9591, createdTime=Mon Feb 15 18:53:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57314, encodeId=47595e31497, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57315, encodeId=9b845e3151b, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57316, encodeId=54b25e316f9, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57317, encodeId=e9305e31765, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-14 medsic

    应该严查!!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1683905, encodeId=0e471683905d1, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Thu Oct 08 05:53:00 CST 2015, time=2015-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672349, encodeId=f06016e234971, content=<a href='/topic/show?id=95c58850418' target=_blank style='color:#2F92EE;'>#虚假#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88504, encryptionId=95c58850418, topicName=虚假)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ab626907756, createdName=doctor-chen9591, createdTime=Mon Feb 15 18:53:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57314, encodeId=47595e31497, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57315, encodeId=9b845e3151b, content=唉……, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57316, encodeId=54b25e316f9, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57317, encodeId=e9305e31765, content=应该严查!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Thu Jan 14 13:08:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-14 medsic

    应该严查!!

    0

相关资讯

CFDA发布关于药物临床试验数据自查情况的公告

按照国家食品药品监督管理总局《关于开展药物临床试验数据自查核查工作的公告》(2015年第117号)要求,药物临床试验数据自查和报告工作于2015年8月25日24时结束。现将自查结果公告如下: 一、本次药物临床试验自查涉及1622个品种。其中,申请人提交自查资料的注册申请为1094个,占 67%;主动撤回的注册申请317个,占20%;申请减免临床试验等不需要提交的注册申请193个,占12%。 二

CFDA:七家药企产品含有松香酸和致癌物苏丹红

国家食品药品监督管理总局(下称“总局”)发布通告,山西旺龙神农药业有限公司等7家药企因产品中检出松香酸或苏丹红被总局点名。 通告称,总局在全国范围内组织对风湿关节炎片和跌打丸2个品种进行了专项监督抽验,分别从药品生产、经营和使用环节抽取了158批次跌打丸和155批次风湿关节炎片。经青岛市食品药品检验检测中心按照补充检验方法检验,发现标示为吉林省通药制药集团股份有限公司和吉林省华侨药业有限公司生产

CFDA:春节消费八大提示 防范食品安全风险

春节是我国重要的传统节日,针对春节期间食品安全特点,国家食品药品监督管理总局(CFDA)提示广大消费者合理防范风险、科学饮食消费。 一、选择购买感官正常的食品或食品原料,特别要观察是否新鲜,是否在保质期内,包装是否完整无损、有无鼓包(涨袋、胖听)等现象。购买保健食品要认准保健食品标志和批准文号。 二、购买熟食或需冷藏的食物时要注意其储运条件应符合产品标示要求。购买后使用冰箱、冰柜等冷藏食品

CFDA拟推60天快速审批抗肿瘤创新药物临床研究申请

药物审批是所有医药开发者最为头痛的环节。而在中国,医药审批较为繁琐的过程也广为医药产业人士诟病。然而2015年来,中国医药相关部门的一系列举措似乎将要改变这一现象。最近,有消息人士透露中国CFDA正考虑以抗肿瘤药物为试点,推行临床试验新药(IND)60天内快速审批的政策。如果属实,中国将成为继新加坡、韩国之后第三个对临床早期研究进行快速审批的亚洲国家。 产业方面消息人士表示,CFDA下属的药

CFDA:2014发布的重要文件一览

2014年,CFDA发布了不少文件,本文盘点了其中20个重要文件。

CFDA全新发布:药品注册流程新规则

食品药品监管总局关于进一步规范药品注册受理工作的通知 食药监药化管〔2015〕122号 2015年07月30日 发布 各省、自治区、直辖市食品药品监督管理局: 为进一步规范药品注册受理工作,现印发《药品注册形式审查补充要求》(见附件),请遵照执行,并将有关要求通知如下: 一、各省级局应严格按照《药品注册管理办法》及相关规定,在5个工作日内完成对申报资料的形式审查,一次性告

Baidu
map
Baidu
map
Baidu
map